Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Add as a preferred source on Google
Bristol Myers Squibb acquired RayzeBio for a staggering amount of $4.1 billion. The global biopharmaceutical company is investing to bolster its cancer therapy portfolio and business.
Terms of the Agreement
This Bristol Myers Squibb deal is the latest one that it has signed in less than a week. It has just announced its purchase of Karuna Therapeutics, a drug developer, on Friday, as per Reuters.
With the buyout deal, Bristol Myers will have access to RayzeBio's drug production facility located in Indianapolis, Indiana. It was agreed that the former would pay $62.50 in cash for every share of RayzeBio.
Looking Forward to Growth as Bristol Myers and RayzeBio Merge
Bristol Myers Squibb's acquisition of RayzeBio is a strategic move that aligns with the recent gush of mergers and acquisition agreements in the pharmaceutical industry. The companies' respective management teams believe this deal will fuel growth within the second half of this decade.
"This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond," Bristol Myers Squibb's chief executive officer, Christopher Boerner, Ph.D., said in a press release. "We look forward to supporting and accelerating RayzeBio's preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform."
RayzeBio's president and CEO, Ken Song, M.D., further stated, "Despite therapeutic advances in recent years, the need for more effective treatments in solid tumors persists, and radiopharmaceutical therapeutics are positioned to be an important next wave of innovation in oncology therapy."
The biotech firm's chief added, "Bristol Myers Squibb's well-established presence in oncology and deep expertise in developing, commercializing, and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution and I am very excited to see what our team clinches as part of Bristol Myers Squibb."
Photo by: Bristol Myers Squibb Media Gallery
